Clinical trial
An Open Label, Multicenter, Single Arm, Phase 1/2 Trial of Metronomic 5-fluorouracil in Combination With Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma.
NCT02620800 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Multicenter, Single Arm, Phase 1/2 Trial of Metronomic 5-fluorouracil in Combination With Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma.
- Lead sponsor
- Celgene
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 18, 2016
- Completion date
- October 29, 2018
- Enrollment
- 12 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic pancreas adenocarcinoma